FDA approves Atossa Genetics' endoxifen for “expanded access” as preoperative systemic endocrine therapy

|About: Atossa Genetics, Inc. (ATOS)|By:, SA News Editor

Atossa Genetics (NASDAQ:ATOS) announces that the FDA has approved an “expanded access” of Atossa’s oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer.

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials.

Shares are up 42% premarket.

Subscribe for full text news in your inbox